Company / Total Debt
IGC Pharma, Inc. Total Debt History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Debt
$134.0K
FY2025
5-year range
$134.0K / $276.0K
FY2021-FY2025
Trend
-2.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Total Debt has declined for 6 consecutive years, from $801,467 in FY2016 to $134,000 in FY2025.
Based on SEC 10-K filings.
$134,000 in FY2025 with a 3-year CAGR of -2.4%.
Improved from $141,000 to $134,000 over the past 2 years.
Total Debt over time
Growth rates
- 3-Year CAGR
- -2.4%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- IGC Pharma, Inc.'s total debt has declined for 4 consecutive years.
- 3-year CAGR of -2.4%, indicating a declining trend.
- In FY2025, total debt decreased 2.2% year-over-year.
- Peak total debt was recorded in FY2016.
Company context
Key Data Points
- Altman Z-Score -13.04 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total DebtValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $134.0K | -2.2% |
| FY2024 | $137.0K | -2.8% |
| FY2023 | $141.0K | -2.1% |
| FY2022 | $144.0K | -47.8% |
| FY2021 | $276.0K | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | $452.1K | -43.6% |
| FY2016 | $801.5K | +147.4% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026